The world needs a global plan to tackle antimicrobial resistance. Alongside a $2B fund to jump-start innovation there should be a $1B reward for companies when a new antibiotic is launched, says Jim O’Neill, chair of the review
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and the fortnightly R&D Express, tracking reforms and investments in central and eastern Europe.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.